Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
← catalyst calendarNCT05826535 · readout in 865 d
Sponsored by Lyell Immunopharma, Inc. (industry) · LYEL — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
270estimated
Sites
34
Countries
Australia, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-05-09 | actual | When the study began enrolling |
| Primary completion | 2028-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2023-04-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Relapsed Non-Hodgkin Lymphoma
- Refractory Non-Hodgkin Lymphoma
- Non-Hodgkin Lymphoma
- Large B-cell Lymphoma
Interventions
- Drug: Rondecabtagene autoleucel (ronde-cel)
- Drug: Fludarabine
- Drug: Cyclophosphamide
Primary outcomes
what the primary-completion date above is the date OFPhase 1: Evaluate the safety and tolerability of a single dose of ronde-cel administered as a single agent
measured Baseline to Month 24
Phase 2: Estimate the efficacy of ronde-cel, as measured by overall response rate (ORR)
measured Baseline to Month 24
Permalink · LYEL's whole pipeline · Catalyst calendar · Every registered study · What changed